Do Tau Tracers Track Cognitive Decline in Disease?
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
68 RESULTS
Sort By:
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Researchers Revel in C9ORF72 Advances at RNA Symposium Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS The Four Stages of TDP-43 Proteinopathy Blocking a MicroRNA Slows Motor Neuron Disease in Mice Glial Cells Refine Neural Circuits Innate Immune
A Conference Devoted to Better Engaging Clinical Trial Volunteers Turning to the Internet for Alzheimer’s Trial Volunteers Patient Engagement in Clinical Trials
Are New Cognitive Tests Ready For Preclinical Trials? Do Tau Tracers Track Cognitive Decline in Disease? Growth Factor Therapy: Safe in Phase 1, Awaiting Efficacy Data Clinical Trials on Alzheimer’s Disease 2013
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
The NIH releases whole-genome data from the Alzheimer’s Sequencing Project.
Thought to be no place for translation, RNA granules that form in “FUSopathies” turn out to host protein synthesis, after all.
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
Cloistered Retreat Takes the Pulse of BACE Research BACE—Substrates, Functions, Developmental Phenotypes Blocking BACE—Do Adult Mouse Phenotypes Predict Side Effects? Meeting Explores Complex Biology of BACE Regulation BACE Proteases in Health and Disease
As new substrates and functions for BACE continue to emerge, scientists worry about adverse effects of blocking the protease.
A European public-private partnership plans to combine faster enrollment with adaptive trials to hasten drug discovery in Alzheimer's.
European Project Mixes Adaptive Design with Trial-Ready Cohort G8 Vows to Improve Care, Cure Dementia G8 Dementia Summit
G8 leaders set 2025 as their goal to find better treatment for Alzheimer's and vowed to coordinate research and care strategies.
Researchers at a meeting on BACE shared concerns that blocking the protease in adults might have unexpected consequences.